Mehmet Akif Guler1, Omer Faruk Celik2, Fikriye Figen Ayhan2,3. 1. Department of Physical Medicine and Rehabilitation, Gaziosmanpasa Taksim Training and Research Hospital, Mevlana District, 884. Street No: 23, 34255 Gaziosmanpasa, Istanbul, Turkey. makifguler89@gmail.com. 2. Department of Physical Medicine and Rehabilitation, Divisions of Rheumatology, Pain Medicine, Health Sciences University, Ankara Training and Research Hospital, Ankara, Turkey. 3. Department of Physical Therapy and Rehabilitation, Usak University, High School of Health Sciences, Usak, Turkey.
Abstract
OBJECTIVE: This study explored the role of central sensitization (CS) pain in patients with various rheumatic diseases using the CS inventory (CSI). METHODS: A total of 193 patients of mean age 50.72 ± 9.65 years were included; they were divided into four different groups in terms of their rheumatic diseases. Patients with rheumatoid arthritis (RA), spondyloarthropathy (SpA), osteoarthritis (OA), and fibromyalgia syndrome (FMS) were evaluated in tertiary care rheumatology/pain medicine settings. Disease duration and activity, the Bath Ankylosing Spondylitis Disease Activity Index, the Disease Activity Score-28, and pain severity (evaluated using a visual analog scale) were assessed, and the Turkish version of the CSI administered. RESULTS: CS syndromes were present in almost half the patients (45% of SpA, 41% of RA, 62% of OA, and 94% of FMS patients). We found no significant relationship between disease activity and the CSI-A scores in SpA or RA patients (p = 0.731 and p = 0.390, respectively). As expected, the CSI-A scores were highest in the FMS group (p = 0.000), but were similar in the other groups (p < 0.05). CS-related syndromes (CSI-B conditions) were present at similar frequencies in the RA, SpA, and OA groups, but were less common in the FMS group (p = 0.000). CONCLUSIONS: The CSI usefully detects CS pain in patients with rheumatic diseases. Treatment of such pain can enhance the quality of daily life in patients with rheumatic diseases.Key Point• Central sensitization pain is common in patients with rheumatic diseases including rheumatoid arthritis, spondyloarthropathies, and osteoarthritis.
OBJECTIVE: This study explored the role of central sensitization (CS) pain in patients with various rheumatic diseases using the CS inventory (CSI). METHODS: A total of 193 patients of mean age 50.72 ± 9.65 years were included; they were divided into four different groups in terms of their rheumatic diseases. Patients with rheumatoid arthritis (RA), spondyloarthropathy (SpA), osteoarthritis (OA), and fibromyalgia syndrome (FMS) were evaluated in tertiary care rheumatology/pain medicine settings. Disease duration and activity, the Bath Ankylosing Spondylitis Disease Activity Index, the Disease Activity Score-28, and pain severity (evaluated using a visual analog scale) were assessed, and the Turkish version of the CSI administered. RESULTS: CS syndromes were present in almost half the patients (45% of SpA, 41% of RA, 62% of OA, and 94% of FMS patients). We found no significant relationship between disease activity and the CSI-A scores in SpA or RApatients (p = 0.731 and p = 0.390, respectively). As expected, the CSI-A scores were highest in the FMS group (p = 0.000), but were similar in the other groups (p < 0.05). CS-related syndromes (CSI-B conditions) were present at similar frequencies in the RA, SpA, and OA groups, but were less common in the FMS group (p = 0.000). CONCLUSIONS: The CSI usefully detects CS pain in patients with rheumatic diseases. Treatment of such pain can enhance the quality of daily life in patients with rheumatic diseases.Key Point• Central sensitization pain is common in patients with rheumatic diseases including rheumatoid arthritis, spondyloarthropathies, and osteoarthritis.
Entities:
Keywords:
Central nervous system sensitization; Osteoarthritis; Rheumatoid arthritis; Spondyloarthropathy
Authors: Mira Meeus; Stijn Vervisch; Luc S De Clerck; Greta Moorkens; Guy Hans; Jo Nijs Journal: Semin Arthritis Rheum Date: 2011-10-28 Impact factor: 5.532
Authors: S Reyes-Long; J L Cortes-Altamirano; D Clavijio-Cornejo; M Gutiérrez; C Bertolazzi; C Bandala; C Pineda; A Alfaro-Rodríguez Journal: Mol Biol Rep Date: 2020-08-01 Impact factor: 2.316
Authors: Marcel Simis; Marta Imamura; Kevin Pacheco-Barrios; Anna Marduy; Paulo S de Melo; Augusto J Mendes; Paulo E P Teixeira; Linamara Battistella; Felipe Fregni Journal: Sci Rep Date: 2022-01-27 Impact factor: 4.379
Authors: Marcel Simis; Marta Imamura; Paulo S de Melo; Anna Marduy; Kevin Pacheco-Barrios; Paulo E P Teixeira; Linamara Battistella; Felipe Fregni Journal: Sci Rep Date: 2021-12-14 Impact factor: 4.379